|
|
Blood, 15 November 2006, Vol. 108, No. 10, pp. 3441-3449.
Prepublished online as a Blood First Edition Paper on June 13, 2006May 25, 2006; DOI 10.1182/blood-2006-04-016055.
 Previous Article | Next Article 
Submitted April 14, 2006
Accepted May 1, 2006
Aggresome induction by proteasome inhibitor bortezomib
and  -tubulin hyperacetylation by tubulin
deacetylase (TDAC) inhibitor LBH589 are synergistic in
myeloma cells
Laurence Catley, Ellen Weisberg, Tanyel Kiziltepe, Yu-Tzu Tai, Teru Hideshima, Paola Neri, Pierfrancesco Tasssone, Peter Atadja, Dharminder Chauhan, Nikhil C Munshi, and Kenneth C Anderson*
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
Novartis Institutes for Biomedical Research, Oncology Research
* Corresponding author; email: kenneth_anderson{at}dfci.harvard.edu.
Histone deacetylase (HDAC) inhibitors have shown
cytotoxicity as single agents in pre-clinical studies
for multiple myeloma (MM) cells. LBH589 is a novel
hydroxamic acid derivative that at low nanomolar
concentrations induces apoptosis in MM cells resistant
to conventional therapies via caspase activation and poly
(ADP-ribose) polymerase (PARP) cleavage. Significant
synergistic cytotoxicity was observed with LBH589 in
combination with bortezomib against MM cells which were
sensitive and resistant to Dexamethasone (Dex), as well
as primary patient MM cells. LBH589 at low nanomolar
concentrations also induced  -tubulin
hyperacetylation. Aggresome formation was observed in
the presence of bortezomib, and the combination of
LBH589 plus bortezomib induced the formation of abnormal
bundles of hyeracetylated -tubulin but with
diminished aggresome size and apoptotic nuclei. These
data confirm the potential clinical benefit of combining
HDAC inhibitors with proteasome inhibitors, and provide
insight into the mechanisms of synergistic anti-MM
activity of bortezomib in combination with LBH589.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Ellis, Y. Pan, G. K. Smyth, D. J. George, C. McCormack, R. Williams-Truax, M. Mita, J. Beck, H. Burris, G. Ryan, et al.
Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
Clin. Cancer Res.,
July 15, 2008;
14(14):
4500 - 4510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kraus, E. Malenke, J. Gogel, H. Muller, T. Ruckrich, H. Overkleeft, H. Ovaa, E. Koscielniak, J. T. Hartmann, and C. Driessen
Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis
Mol. Cancer Ther.,
July 1, 2008;
7(7):
1940 - 1948.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. De Bruyne, T. J. Bos, K. Asosingh, I. Vande Broek, E. Menu, E. Van Valckenborgh, P. Atadja, V. Coiteux, X. Leleu, K. Thielemans, et al.
Epigenetic Silencing of the Tetraspanin CD9 during Disease Progression in Multiple Myeloma Cells and Correlation with Survival
Clin. Cancer Res.,
May 15, 2008;
14(10):
2918 - 2926.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Scuto, M. Kirschbaum, C. Kowolik, L. Kretzner, A. Juhasz, P. Atadja, V. Pullarkat, R. Bhatia, S. Forman, Y. Yen, et al.
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells
Blood,
May 15, 2008;
111(10):
5093 - 5100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Hassig, K. T. Symons, X. Guo, P.-M. Nguyen, T. Annable, P. L. Wash, J. E. Payne, D. A. Jenkins, C. Bonnefous, C. Trotter, et al.
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
Mol. Cancer Ther.,
May 1, 2008;
7(5):
1054 - 1065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Dai, S. Chen, L. B. Kramer, V. L. Funk, P. Dent, and S. Grant
Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells
Clin. Cancer Res.,
January 15, 2008;
14(2):
549 - 558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Yu, B. B. Friday, L. Yang, P. Atadja, D. Wigle, J. Sarkaria, and A. A. Adjei
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells
Neuro-oncol,
January 1, 2008;
10(3):
309 - 319.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Yu, B. B. Friday, J.-P. Lai, A. McCollum, P. Atadja, L. R. Roberts, and A. A. Adjei
Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation
Clin. Cancer Res.,
February 15, 2007;
13(4):
1140 - 1148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Trudel, A. K. Stewart, Z. Li, Y. Shu, S.-B. Liang, Y. Trieu, D. Reece, J. Paterson, D. Wang, and X.-Y. Wen
The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan
Clin. Cancer Res.,
January 15, 2007;
13(2):
621 - 629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
